CATALYSTYahoo Finance • 23h ago
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?Yahoo Finance report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
Why KRRO Stock surged +10.69% Today — RQD Quant Desk Flash
$15.85 +10.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $16.12
Korro Bio Inc. (KRRO) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $210.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on KRRO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is KRRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Korro Bio Inc. (NASDAQ: KRRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $15.85 (+10.69% 1D, market cap $210.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, KRRO ranks #464 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does KRRO compare to BBOT and NATR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRRO carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BBOT (BridgeBio Oncology Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $210.1M) and NATR (Nature's Sunshine Products Inc.) posts a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $215.5M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while SIGA leads on capital efficiency (42.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for KRRO?
▼
Per KRRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703647), Korro Bio Inc. generated $6.4M in revenue (+181.5% YoY), -$117.3M in net income, and -$79.1M in free cash flow against $113.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $16.12 (+1.73%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRRO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY KRRO SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)
FRED Regime × Technicals: 29% of 52W Range • RSI-14 at 71.4 (OVERBOUGHT (>70))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$8.81+7.2% Next Q
32
Q2 (-2Q)Grade E$9.44+40.9% Next Q
35
Q3 (-1Q)Grade E$13.30+19.2% Next Q
37
CurrentGrade D-$15.85-7.4% Hist 90D α
40
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a KRRO Turnaround Squeeze
While KRRO currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.45) and Max Pain ($16.64) forces dealer call-delta covering toward $43.63.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRRO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KRRO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KRRO Stock surged +10.69% Today — RQD Quant Desk Flash
Korro Bio Inc. (KRRO) surged +10.69% to $15.85, trading at 29% of its 52-week range ($5.2 – $41.55). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 29% of its 52-week range ($5.2 – $41.55) with RSI-14 at 71.4 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $15.85 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live KRRO Headlines & Catalysts
MARKET WIREInvesting.com • 1d ago
H.C. Wainwright reiterates Korro Bio stock rating on trial dosingInvesting.com report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?Simply Wall St report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stockInvesting.com report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Across three dates, Lynx1 Master Fund buys 79,809 Korro Bio (KRRO) shares.Stock Titan report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Korro Bio (KRRO) Slides 8.81% to $8.49, Drifting Toward Key Support - Supply Zonehttps://www.siam.in/ report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
BlackRock units amend their Korro Bio (KRRO) stake disclosure, excluding other business units.Stock Titan report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
Korro Bio (KRRO) Slips 0.21% to $9.62, Trading Mid-Range Between Key Levels - Merger Arbitragehttps://www.dars.gov.et/ report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 1d ago
Kosmos Energy Shares Fall Over 10% After Q3 Earnings and Revenue Miss ForecastsKosmos Energy (NASDAQ:KRRO) shares declined more than 10% in pre-market trading after the oil and gas producer reported third-quarter 2026 earnings and revenue below analysts’ expectations, despite higher production, low
MARKET WIREBenzinga • 7d ago
Reported Oct. 26: Korro Bio Shareholder Lynx1 Capital Management Buys 79,809 Shares At An Average Price Of $11.09/Sharehttps://www.sec.gov/Archives/edgar/data/1703647/000090266426004286/xslF345X06/ownership.xml
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRRO)
- ✓Walkthrough of KRRO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KRRO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.64%▲ RESISTANCE BREAKOUT
2026-11-03O $14.20H $15.85L $14.20C $15.85VOL 130.8K
RES: $14.86SUP: $8.03SMA50: $11.45SMA200: $11.99
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KRRO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +181.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on KRRO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KRRO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRRO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRRO)
Health Care Rank #464 of 1015
⚔️ BBOT vs KRRO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KRRO vs. BBOT, NATR, PYXS, SIGA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Korro Bio Inc. (KRRO) ranks #464 by composite RQD confidence (40/100, grade D-) and #565 by equity capitalization ($210.8M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while SIGA leads on capital efficiency and profitability with 42.7% ROIC and 68.6% gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with KRRO at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KRRO
ACTIVE
Korro Bio Inc. | D- | 40/100 | — | — | -35.0% | +10.69% | $210.8M | Benchmark Subject |
| BBOT BridgeBio Oncology Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -11.83% | $210.1M | /bbot-vs-krro → |
| NATR Nature's Sunshine Products Inc. | C | 64/100 | 11.1x | 72.4% | 28.9% | -1.88% | $215.5M | /natr-vs-krro → |
| PYXS Pyxis Oncology Inc. | E | 27/100 | — | 82.8% | -35.0% | -6.63% | $216.4M | /pyxs-vs-krro → |
| SIGA SIGA Technologies Inc. | C+ | 68/100 | 9.8x | 68.6% | 42.7% | -2.96% | $218.4M | /siga-vs-krro → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001703647 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Korro Bio Inc. (KRRO) reported GAAP revenue of $6.4M (+181.5% vs. FY2024 revenue of $2.3M , and -97.3% cumulative change since FY2023) , GAAP net income of -$117.3M, operating cash flow of -$78.6M, and free cash flow of -$79.1M (-1.4% YoY). On the balance sheet, KRRO closed FY2025 with $113.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.4M | -$117.3M | -$78.6M | -$79.1M | $113.5M | — |
| FY2024 (FY) | 2024-12-31 | $2.3M | -$83.6M | -$60.1M | -$78.0M | $226.2M | — |
| FY2023 (FY) | 2023-12-31 | $236.7M | -$81.2M | -$67.3M | -$67.3M | — | — |
3. KRRO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KRRO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Korro Bio Inc. (NASDAQ: KRRO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $15.85 (+10.69% 1D, market cap $210.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, KRRO ranks #464 in composite RQD confidence.
How does KRRO compare to BBOT and NATR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KRRO carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BBOT (BridgeBio Oncology Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $210.1M) and NATR (Nature's Sunshine Products Inc.) posts a C grade (64/100 RQD, P/E 11.1x, ROIC 28.9%, cap $215.5M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while SIGA leads on capital efficiency (42.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KRRO?
Per KRRO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001703647), Korro Bio Inc. generated $6.4M in revenue (+181.5% YoY), -$117.3M in net income, and -$79.1M in free cash flow against $113.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KRRO trading relative to its 50-day, 200-day, and 52-week technical levels?
KRRO last traded at $15.85 (+10.69% on volume of 206,772 shares), positioning the stock +38.43% above its 50-day simple moving average ($11.45) and +32.19% above its 200-day simple moving average ($11.99). Across its 52-week range of $5.20 to $41.55, KRRO sits at the 29.3% percentile with a 14-day RSI of 71.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($13.87 to $17.83).
ROARABLE RATING BRIEF • RQD 40/100 (D-)
✓ SEC XBRL & RQD VERIFIED
KRRO — Korro Bio Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Korro Bio Inc. (KRRO) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $15.85 (+10.69% 1D, market capitalization $210.8M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (12/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Korro Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Korro Bio Inc. (KRRO) reported $6.4M in annual revenue (up from $2.3M in FY2024, +181.5% YoY) and -$117.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($236.7M revenue, -$81.2M net income) through FY2025, KRRO scaled operating cash flow to -$78.6M and free cash flow to -$79.1M, backed by $113.5M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 12/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $5.20 – $41.55 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No supply-chain dependencies, butterfly links, or proprietary signals are recorded. Upstream and downstream relationships, sector correlations, and 2nd-order bottlenecks are therefore — The only sector context provided is the Health Care / Biotechnology: Pharmaceutical Preparations classification and the RQD macro regime score, which reflects sector sensitivity but does not identify specific ripple channels.
- Key Question #1: Can KRRO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $6.4M and free cash flow of -$79.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is KRRO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
KRRO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Korro Bio Inc. (KRRO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 23h ago
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains? Yahoo Finance report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
H.C. Wainwright reiterates Korro Bio stock rating on trial dosing Investing.com report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely? Simply Wall St report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stock Investing.com report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Across three dates, Lynx1 Master Fund buys 79,809 Korro Bio (KRRO) shares. Stock Titan report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Korro Bio (KRRO) Slides 8.81% to $8.49, Drifting Toward Key Support - Supply Zone https://www.siam.in/ report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
BlackRock units amend their Korro Bio (KRRO) stake disclosure, excluding other business units. Stock Titan report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
Korro Bio (KRRO) Slips 0.21% to $9.62, Trading Mid-Range Between Key Levels - Merger Arbitrage https://www.dars.gov.et/ report covering Korro Bio Inc. (KRRO) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
KRRO Bull vs. Bear Conversation Board — What's Your Call at $15.85?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRRO 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $18.76 (+31.0%)
📌 Pinned Debate Institutional accumulation and a 10% owner's purchases signal active whale buying, supported by a 29.7% surge headline.
Don't sleep on KRRO's setup in Health Care. Institutional accumulation and a 10% owner's purchases signal active whale buying, supported by a 29.7% surge headline.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (40/100) backs up the fundamental quality.
RetailWhale_TX 🐂 BULL
@CreditSpread_Watch Shorting a 12/20 institutional whale-flow stock at $14.32 is dangerous when funds are rotating into Health Care.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $12.03 (-16.0%)
Spot @ $14.32 Operating losses of -$121.9M against $21.8M of cash, with ROIC at -35% and insider conviction scoring only 3 / 20.
I respect the product at Korro Bio Inc., but the stock at $14.32 is a different story. Operating losses of -$121.9M against $21.8M of cash, with ROIC at -35% and insider conviction scoring only 3 / 20.. FCF yield is 0.0% and RQD sits at 40/100 (D-) — why pay up here when you can wait for next quarter's numbers?